OptiNose (OPTN) Tops Q1 EPS by 4c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St futures muted as investors monitor US-Iran negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Optinose Reports First Quarter 2021 Financial Results and Operational Updates
May 5, 2021 7:00 AM EDTCompany reports first quarter total revenue of $12.0 million
First quarter 2021 XHANCE net revenue of $11.0 million increased 55% compared to first quarter 2020
Conference call and webcast to be held today at 8:00 a.m. Eastern Time
YARDLEY, Pa., May 05, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter ended March 31, 2021, and provided operational updates.
XHANCE net revenues increased 55% in the... More
